» Articles » PMID: 36140294

Clinical Usefulness of Non-Invasive Metabolic-Associated Fatty Liver Disease Risk Assessment Methods in Patients with Full-Blown Polycystic Ovary Syndrome in Relation to the MRI Examination with the Ideal IQ Sequence

Overview
Journal Biomedicines
Date 2022 Sep 23
PMID 36140294
Authors
Affiliations
Soon will be listed here.
Abstract

The coexistence of polycystic ovary syndrome (PCOS) and liver steatosis has been studied for years. The gold standards for the diagnosis of liver steatosis are liver biopsy and magnetic resonance imaging (MRI), which are invasive and expensive methods. The main aim of this study is to check the usefulness of lipid accumulation product (LAP) and free androgen index (FAI) in the diagnosis of liver steatosis. The Ideal IQ MRI was performed in 49 women with PCOS phenotype A to assess the degree of liver steatosis, which was expressed with the proton density fat fraction (PDFF). Anthropometric examination and laboratory tests were performed, and the LAP and FAI were calculated. The correlation between MRI results and LAP, FAI, and one of the FAI components, sex hormone binding globulin (SHBG), was checked using statistical tests. There is a statistically significant correlation between PDFF and LAP and also between PDFF and FAI. LAP = 70.25 and FAI = 5.05 were established as cut-offs to diagnose liver steatosis. The SHBG is not a statistically significant parameter to predict liver steatosis. The study showed that especially LAP, but also FAI, can be used to predict liver steatosis with high specificity and sensitivity.

Citing Articles

Biochemical, sex hormonal, and anthropometric predictors of non-alcoholic fatty liver disease in polycystic ovary syndrome.

Li X, Min M, Duan F, Ruan X, Xu L BMC Womens Health. 2025; 25(1):118.

PMID: 40087649 DOI: 10.1186/s12905-025-03648-9.


Evaluation of ultrasound derived fat fraction for metabolic associated fatty liver disease in obese patients with polycystic ovary syndrome.

Meng L, Yang H, Hu Y, Jiang Y, Yang Z J Ultrasound. 2025; .

PMID: 39904953 DOI: 10.1007/s40477-024-00982-w.


Quantitative assessment of renal steatosis in patients with type 2 diabetes mellitus using the iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence imaging: repeatability and clinical....

Liu J, Wu Y, Tian C, Zhang X, Su Z, Nie L Quant Imaging Med Surg. 2024; 14(10):7341-7352.

PMID: 39429570 PMC: 11485345. DOI: 10.21037/qims-24-330.

References
1.
Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D . Ultrasound examination of polycystic ovaries: is it worth counting the follicles?. Hum Reprod. 2003; 18(3):598-603. DOI: 10.1093/humrep/deg115. View

2.
Spremovic Radenovic S, Pupovac M, Andjic M, Bila J, Sreckovic S, Gudovic A . Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS). Biomedicines. 2022; 10(1). PMC: 8773533. DOI: 10.3390/biomedicines10010131. View

3.
Placzkowska S, Pawlik-Sobecka L, Kokot I, Piwowar A . Indirect insulin resistance detection: Current clinical trends and laboratory limitations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019; 163(3):187-199. DOI: 10.5507/bp.2019.021. View

4.
Lim S, Hutchison S, Van Ryswyk E, Norman R, Teede H, Moran L . Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019; 3:CD007506. PMC: 6438659. DOI: 10.1002/14651858.CD007506.pub4. View

5.
Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View